5-amino-2-(4-chloro-phenyl)-oxazole-4-carbonitrile | 53657-72-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-amino-2-(4-chloro-phenyl)-oxazole-4-carbonitrile
• 英文别名: 5-Amino-2-(4-chlorophenyl)-1,3-oxazole-4-carbonitrile
• CAS: 53657-72-0
• 化学式: C₁₀H₆ClN₃O
• 分子量: 219.63
• InChiKey: RKPAHDNYELCQRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-amino-2-(4-chloro-phenyl)-oxazole-4-carbonitrile 在 硫酸 作用下， 生成 5-Amino-2-(4-chloro-phenyl)-oxazole-4-carboxylic acid amide
  参考文献：
  名称：

  Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β:  Part I:  Hit-to-Lead Strategies

  摘要：

  High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of I kappa B kinase-beta (IKK beta), a key regulatory enzyme in the nuclear factor-kappa B (NF-kappa B) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering additional opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.

  DOI：

  10.1021/jm0510979
• 作为产物：
  描述：

  3-(4-chloro-phenyl)-2-cyano-1-phthalimido-aziridine-2-carboxylic acid amide 以 苯 为溶剂， 生成 5-amino-2-(4-chloro-phenyl)-oxazole-4-carbonitrile
  参考文献：
  名称：

  Person,H. et al., Bulletin de la Societe Chimique de France, 1976, p. 1989 - 1992

  摘要：

  DOI：

文献信息

• Potent and Selective Inhibitors of Human Reticulocyte 12/15-Lipoxygenase as Anti-Stroke Therapies
  作者：Ganesha Rai、Netra Joshi、Joo Eun Jung、Yu Liu、Lena Schultz、Adam Yasgar、Steve Perry、Giovanni Diaz、Qiangli Zhang、Victor Kenyon、Ajit Jadhav、Anton Simeonov、Eng H. Lo、Klaus van Leyen、David J. Maloney、Theodore R. Holman

  DOI：10.1021/jm401915r

  日期：2014.5.22

  A key challenge facing drug discovery today is variability of the drug target between species, such as with 12/15-lipoxygenase (12/15-LOX), which contributes to ischemic brain injury, but its human and rodent isozymes have different inhibitor specificities. In the current work, we have utilized a quantitative high-throughput (qHTS) screen to identify compound 1 (ML351), a novel chemotype for 12/15-LOX inhibition that has nanomolar potency (IC50 = 200 nM) against human 12/15-LOX and is protective against oxidative glutamate toxicity in mouse neuronal HT22 cells. In addition, it exhibited greater than 250-fold selectivity versus related LOX isozymes, was a mixed inhibitor, and did not reduce the active-site ferric ion. Lastly, 1 significantly reduced infarct size following permanent focal ischemia in a mouse model of ischemic stroke. As such, this represents the first report of a selective inhibitor of human 12/15-LOX with demonstrated in vivo activity in proof-of-concept mouse models of stroke.
• Synthesis, biological evaluation and molecular modelling of diversely functionalized heterocyclic derivatives as inhibitors of acetylcholinesterase/butyrylcholinesterase and modulators of Ca2+ channels and nicotinic receptors
  作者：José L Marco、Cristóbal de los Rı́os、Antonio G Garcı́a、Mercedes Villarroya、M.Carmo Carreiras、Carla Martins、Ana Eleutério、Antonio Morreale、M Orozco、F.Javier Luque

  DOI：10.1016/j.bmc.2004.02.017

  日期：2004.5

  The synthesis and the biological activity of compounds 5-40 as inhibitors of acetyleholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as modulators of voltage-dependent Ca2+ channels and nicotinic receptors, are described. These molecules are tacrine analogues, which have been prepared from polyfunctionalized 6-amino-5-cyano-4H-pyrans, 6-amino-5-cyano-pyridines and 5-amino-2-aryl-3-cyano-1,3-oxazoles via Friedlander reaction with selected cycloalkanones. These compounds are moderate acetylcholinesterase and butyrylcholinesterase inhibitors, the BuChE/AChE selectivity of the most active molecules ranges from 10.0 (compound 29) to 76.9 (compound 16). Interestingly, the 'oxazolo-tacrine' derivatives are devoid of any activity. All compounds showed an important inhibitory effect on the nicotinic acetylcholine receptor. Most of them also blocked L-type Ca2+ channels, and three of them, 64, 19 and 67, the non-L type of Ca2+ channels. Molecular modelling studies suggest that these compounds might bind at the peripheral binding site of AChE, which opens the possibility to design inhibitors able to bind at both, the catalytic and peripheral binding sites of the enzyme. (C) 2004 Elsevier Ltd. All rights reserved.
• PERSON H.; LUANGLATH K.; BAUDRU M.; FOUCAND A., BULL. SOC. CHIM. FRANCE, 1976, NO 11-12, PART. 2, 1989-1992
  作者：PERSON H.、 LUANGLATH K.、 BAUDRU M.、 FOUCAND A.

  DOI：——

  日期：——
• Evolution of the Thienopyridine Class of Inhibitors of IκB Kinase-β:  Part I:  Hit-to-Lead Strategies
  作者：Tina Morwick、Angela Berry、Janice Brickwood、Mario Cardozo、Katrina Catron、Molly DeTuri、Jonathan Emeigh、Carol Homon、Matt Hrapchak、Stephen Jacober、Scott Jakes、Paul Kaplita、Terence A. Kelly、John Ksiazek、Michel Liuzzi、Ronald Magolda、Can Mao、Daniel Marshall、Daniel McNeil、Anthony Prokopowicz、Christopher Sarko、Erika Scouten、Cynthia Sledziona、Sanxing Sun、Jane Watrous、Jiang Ping Wu、Charles L. Cywin

  DOI：10.1021/jm0510979

  日期：2006.5.1

  High-throughput screening is routinely employed as a method for the identification of novel hit structures. Large numbers of active compounds are typically procured in this way and must undergo a rigorous validation process. This process is described in detail for a collection of screening hits identified as inhibitors of I kappa B kinase-beta (IKK beta), a key regulatory enzyme in the nuclear factor-kappa B (NF-kappa B) pathway. From these studies, a promising hit series was selected. Subsequent lead generation activities included the development of a pharmacophore hypothesis and structure-activity relationship (SAR) for the hit series. This led to the exploration of related scaffolds offering additional opportunities, and the various structural classes were comparatively evaluated for enzyme inhibition, selectivity, and drug-like properties. A novel lead series of thienopyridines was thereby established, and this series advanced into lead optimization for further development.
• Person,H. et al., Bulletin de la Societe Chimique de France, 1976, p. 1989 - 1992
  作者：Person,H. et al.

  DOI：——

  日期：——